Time trends in the use of curative treatment in men 70 years and older with nonmetastatic prostate cancer
Acta Oncol. 2024 Mar 20;63:95-104. doi: 10.2340/1651-226X.2024.26189.ABSTRACTBACKGROUND: Undertreatment of otherwise healthy men in their seventies with prostate cancer has been reported previously.MATERIAL AND METHODS: Using information in a Swedish prostate cancer research database, patterns of management and cancer-specific mortality were compared across age groups in over 70,000 men diagnosed with intermediate- or high-risk nonmetastatic prostate cancer between 2008 and 2020. Crude probabilities of death were estimated non-parametrically. Staging procedures, primary treatment, and cancer death were compared using regre...
Source: Acta Oncologica - March 20, 2024 Category: Cancer & Oncology Authors: Frida Lundberg David Robinson Ola Bratt Giuseppe Fallara Mats Lambe Anna L V Johansson Source Type: research
Time trends in the use of curative treatment in men 70 years and older with nonmetastatic prostate cancer
Acta Oncol. 2024 Mar 20;63:95-104. doi: 10.2340/1651-226X.2024.26189.ABSTRACTBACKGROUND: Undertreatment of otherwise healthy men in their seventies with prostate cancer has been reported previously.MATERIAL AND METHODS: Using information in a Swedish prostate cancer research database, patterns of management and cancer-specific mortality were compared across age groups in over 70,000 men diagnosed with intermediate- or high-risk nonmetastatic prostate cancer between 2008 and 2020. Crude probabilities of death were estimated non-parametrically. Staging procedures, primary treatment, and cancer death were compared using regre...
Source: Acta Oncologica - March 20, 2024 Category: Cancer & Oncology Authors: Frida Lundberg David Robinson Ola Bratt Giuseppe Fallara Mats Lambe Anna L V Johansson Source Type: research
Time trends in the use of curative treatment in men 70 years and older with nonmetastatic prostate cancer
Acta Oncol. 2024 Mar 20;63:95-104. doi: 10.2340/1651-226X.2024.26189.ABSTRACTBACKGROUND: Undertreatment of otherwise healthy men in their seventies with prostate cancer has been reported previously.MATERIAL AND METHODS: Using information in a Swedish prostate cancer research database, patterns of management and cancer-specific mortality were compared across age groups in over 70,000 men diagnosed with intermediate- or high-risk nonmetastatic prostate cancer between 2008 and 2020. Crude probabilities of death were estimated non-parametrically. Staging procedures, primary treatment, and cancer death were compared using regre...
Source: Acta Oncologica - March 20, 2024 Category: Cancer & Oncology Authors: Frida Lundberg David Robinson Ola Bratt Giuseppe Fallara Mats Lambe Anna L V Johansson Source Type: research
Time trends in the use of curative treatment in men 70 years and older with nonmetastatic prostate cancer
Acta Oncol. 2024 Mar 20;63:95-104. doi: 10.2340/1651-226X.2024.26189.ABSTRACTBACKGROUND: Undertreatment of otherwise healthy men in their seventies with prostate cancer has been reported previously.MATERIAL AND METHODS: Using information in a Swedish prostate cancer research database, patterns of management and cancer-specific mortality were compared across age groups in over 70,000 men diagnosed with intermediate- or high-risk nonmetastatic prostate cancer between 2008 and 2020. Crude probabilities of death were estimated non-parametrically. Staging procedures, primary treatment, and cancer death were compared using regre...
Source: Acta Oncologica - March 20, 2024 Category: Cancer & Oncology Authors: Frida Lundberg David Robinson Ola Bratt Giuseppe Fallara Mats Lambe Anna L V Johansson Source Type: research
Time trends in the use of curative treatment in men 70 years and older with nonmetastatic prostate cancer
Acta Oncol. 2024 Mar 20;63:95-104. doi: 10.2340/1651-226X.2024.26189.ABSTRACTBACKGROUND: Undertreatment of otherwise healthy men in their seventies with prostate cancer has been reported previously.MATERIAL AND METHODS: Using information in a Swedish prostate cancer research database, patterns of management and cancer-specific mortality were compared across age groups in over 70,000 men diagnosed with intermediate- or high-risk nonmetastatic prostate cancer between 2008 and 2020. Crude probabilities of death were estimated non-parametrically. Staging procedures, primary treatment, and cancer death were compared using regre...
Source: Acta Oncologica - March 20, 2024 Category: Cancer & Oncology Authors: Frida Lundberg David Robinson Ola Bratt Giuseppe Fallara Mats Lambe Anna L V Johansson Source Type: research
Time trends in the use of curative treatment in men 70 years and older with nonmetastatic prostate cancer
Acta Oncol. 2024 Mar 20;63:95-104. doi: 10.2340/1651-226X.2024.26189.ABSTRACTBACKGROUND: Undertreatment of otherwise healthy men in their seventies with prostate cancer has been reported previously.MATERIAL AND METHODS: Using information in a Swedish prostate cancer research database, patterns of management and cancer-specific mortality were compared across age groups in over 70,000 men diagnosed with intermediate- or high-risk nonmetastatic prostate cancer between 2008 and 2020. Crude probabilities of death were estimated non-parametrically. Staging procedures, primary treatment, and cancer death were compared using regre...
Source: Acta Oncologica - March 20, 2024 Category: Cancer & Oncology Authors: Frida Lundberg David Robinson Ola Bratt Giuseppe Fallara Mats Lambe Anna L V Johansson Source Type: research
Stable glioma incidence and increased patient survival over the past two decades in Norway: a nationwide registry-based cohort study
Acta Oncol. 2024 Mar 19;63:83-94. doi: 10.2340/1651-226X.2024.24970.ABSTRACTBACKGROUND: Surveillance of incidence and survival of central nervous system tumors is essential to monitor disease burden and epidemiological changes, and to allocate health care resources. Here, we describe glioma incidence and survival trends by histopathology group, age, and sex in the Norwegian population.MATERIAL AND METHODS: We included patients with a histologically verified glioma reported to the Cancer Registry of Norway from 2002 to 2021 (N = 7,048). Population size and expected mortality were obtained from Statistics Norway. Cases were ...
Source: Acta Oncologica - March 19, 2024 Category: Cancer & Oncology Authors: Erlend Skaga Cassia B Trewin-Nybr åten Pitt Niehusmann Tom B ørge Johannesen Kirsten Marienhagen Leif Oltedal Stephanie Schipman Anne Jarstein Skjulsvik Ole Solheim Tora Skeidsvoll Solheim Terje Sundstr øm Einar O Vik-Mo None Petter Brandal Tor Ingebri Source Type: research
Implementing MyChoice ® CDx HRD testing for the Nordics: lessons from 2021 to 2023
Acta Oncol. 2024 Mar 14;63:70-75. doi: 10.2340/1651-226X.2024.34139.ABSTRACTBACKGROUND: Assessment of homologous recombinant deficient (HRD) phenotypes is key for managing Poly (ADP-ribose) polymerase inhibitor (PARPi) treatment. To accommodate the need for a validated HRD platform and enhance targeted treatment of ovarian cancer patients, a Nordic core facility for the myChoice® CDx platform was established in Denmark.MATERIALS AND METHODS: Comparative calculations and statistics are based on information from test requisitions and results (Genome Instability Score [GIS], BRCA status and combined HRD status) obtained from...
Source: Acta Oncologica - March 14, 2024 Category: Cancer & Oncology Authors: Lea Milling Korsholm Verena Broecker Mansoor Raza Mirza Maria Rossing Source Type: research
Health-related quality of life, needs, and concerns among cancer survivors referred to rehabilitation in primary healthcare setting
This study aims to describe challenges faced by cancer survivors (CSs) referred for rehabilitation in primary healthcare, employing standardized scales measuring health-related quality of life (HRQOL) and open-ended questions. Furthermore, the study explores the applicability of patient-reported outcomes (PROs) in comprehensively understanding challenges encountered by CSs.MATERIAL AND METHODS: This cross-sectional study involves CSs referred for cancer rehabilitation in a primary healthcare setting, including those participating in PROs as a part of routine practice. HRQOL was assessed using the Functional Assessment of C...
Source: Acta Oncologica - March 14, 2024 Category: Cancer & Oncology Authors: Mette T Sandager Sine Rossen Dorte T Hofland Claus V Nielsen Thomas Maribo Source Type: research
Implementing MyChoice ® CDx HRD testing for the Nordics: lessons from 2021 to 2023
Acta Oncol. 2024 Mar 14;63:70-75. doi: 10.2340/1651-226X.2024.34139.ABSTRACTBACKGROUND: Assessment of homologous recombinant deficient (HRD) phenotypes is key for managing Poly (ADP-ribose) polymerase inhibitor (PARPi) treatment. To accommodate the need for a validated HRD platform and enhance targeted treatment of ovarian cancer patients, a Nordic core facility for the myChoice® CDx platform was established in Denmark.MATERIALS AND METHODS: Comparative calculations and statistics are based on information from test requisitions and results (Genome Instability Score [GIS], BRCA status and combined HRD status) obtained from...
Source: Acta Oncologica - March 14, 2024 Category: Cancer & Oncology Authors: Lea Milling Korsholm Verena Broecker Mansoor Raza Mirza Maria Rossing Source Type: research
Health-related quality of life, needs, and concerns among cancer survivors referred to rehabilitation in primary healthcare setting
This study aims to describe challenges faced by cancer survivors (CSs) referred for rehabilitation in primary healthcare, employing standardized scales measuring health-related quality of life (HRQOL) and open-ended questions. Furthermore, the study explores the applicability of patient-reported outcomes (PROs) in comprehensively understanding challenges encountered by CSs.MATERIAL AND METHODS: This cross-sectional study involves CSs referred for cancer rehabilitation in a primary healthcare setting, including those participating in PROs as a part of routine practice. HRQOL was assessed using the Functional Assessment of C...
Source: Acta Oncologica - March 14, 2024 Category: Cancer & Oncology Authors: Mette T Sandager Sine Rossen Dorte T Hofland Claus V Nielsen Thomas Maribo Source Type: research
Implementing MyChoice ® CDx HRD testing for the Nordics: lessons from 2021 to 2023
Acta Oncol. 2024 Mar 14;63:70-75. doi: 10.2340/1651-226X.2024.34139.ABSTRACTBACKGROUND: Assessment of homologous recombinant deficient (HRD) phenotypes is key for managing Poly (ADP-ribose) polymerase inhibitor (PARPi) treatment. To accommodate the need for a validated HRD platform and enhance targeted treatment of ovarian cancer patients, a Nordic core facility for the myChoice® CDx platform was established in Denmark.MATERIALS AND METHODS: Comparative calculations and statistics are based on information from test requisitions and results (Genome Instability Score [GIS], BRCA status and combined HRD status) obtained from...
Source: Acta Oncologica - March 14, 2024 Category: Cancer & Oncology Authors: Lea Milling Korsholm Verena Broecker Mansoor Raza Mirza Maria Rossing Source Type: research
Health-related quality of life, needs, and concerns among cancer survivors referred to rehabilitation in primary healthcare setting
This study aims to describe challenges faced by cancer survivors (CSs) referred for rehabilitation in primary healthcare, employing standardized scales measuring health-related quality of life (HRQOL) and open-ended questions. Furthermore, the study explores the applicability of patient-reported outcomes (PROs) in comprehensively understanding challenges encountered by CSs.MATERIAL AND METHODS: This cross-sectional study involves CSs referred for cancer rehabilitation in a primary healthcare setting, including those participating in PROs as a part of routine practice. HRQOL was assessed using the Functional Assessment of C...
Source: Acta Oncologica - March 14, 2024 Category: Cancer & Oncology Authors: Mette T Sandager Sine Rossen Dorte T Hofland Claus V Nielsen Thomas Maribo Source Type: research
Implementing MyChoice ® CDx HRD testing for the Nordics: lessons from 2021 to 2023
Acta Oncol. 2024 Mar 14;63:70-75. doi: 10.2340/1651-226X.2024.34139.ABSTRACTBACKGROUND: Assessment of homologous recombinant deficient (HRD) phenotypes is key for managing Poly (ADP-ribose) polymerase inhibitor (PARPi) treatment. To accommodate the need for a validated HRD platform and enhance targeted treatment of ovarian cancer patients, a Nordic core facility for the myChoice® CDx platform was established in Denmark.MATERIALS AND METHODS: Comparative calculations and statistics are based on information from test requisitions and results (Genome Instability Score [GIS], BRCA status and combined HRD status) obtained from...
Source: Acta Oncologica - March 14, 2024 Category: Cancer & Oncology Authors: Lea Milling Korsholm Verena Broecker Mansoor Raza Mirza Maria Rossing Source Type: research
Health-related quality of life, needs, and concerns among cancer survivors referred to rehabilitation in primary healthcare setting
This study aims to describe challenges faced by cancer survivors (CSs) referred for rehabilitation in primary healthcare, employing standardized scales measuring health-related quality of life (HRQOL) and open-ended questions. Furthermore, the study explores the applicability of patient-reported outcomes (PROs) in comprehensively understanding challenges encountered by CSs.MATERIAL AND METHODS: This cross-sectional study involves CSs referred for cancer rehabilitation in a primary healthcare setting, including those participating in PROs as a part of routine practice. HRQOL was assessed using the Functional Assessment of C...
Source: Acta Oncologica - March 14, 2024 Category: Cancer & Oncology Authors: Mette T Sandager Sine Rossen Dorte T Hofland Claus V Nielsen Thomas Maribo Source Type: research
